Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-03-16 5:10 pm Purchase | 13G | AcuityAds Holdings Inc. ATY | K2 PRINCIPAL FUND L.P. | 3,198,531 5.63% | 350,415 (+12.30%) | View |
| 2023-03-16 5:06 pm Purchase | 13G | AcuityAds Holdings Inc. ATY | K2 PRINCIPAL FUND L.P. | 2,848,116 5.01% | 2,848,116 (New Position) | View |
| 2023-02-13 4:48 pm Purchase | 13G | San Juan Basin Royalty Trust SJT | K2 PRINCIPAL FUND L.P. | 2,367,933 5.08% | 1,061,124 (+81.20%) | View |
| 2023-02-13 4:43 pm Sale | 13G | San Juan Basin Royalty Trust SJT | K2 PRINCIPAL FUND L.P. | 1,306,809 2.8% | -1,033,159 (-44.15%) | View |
| 2023-02-13 4:39 pm Sale | 13G | Solid Biosciences Inc. SLDB | K2 PRINCIPAL FUND L.P. | 284,871 1.46% | -5,424,329 (-95.01%) | View |
| 2023-02-13 4:32 pm Purchase | 13G | ARS Pharmaceuticals, Inc. SPRY | K2 PRINCIPAL FUND L.P. | 2,045,348 2.2% | 138,730 (+7.28%) | View |
| 2023-02-08 5:51 pm Sale | 13G | TCR2 Therapeutics Inc. TCRR | K2 PRINCIPAL FUND L.P. | 0 0% | -1,950,628 (Position Closed) | View |
| 2023-02-08 5:22 pm Sale | 13G | Goldenstone Acquisition Limited GDST | K2 PRINCIPAL FUND L.P. | 0 0% | -375,000 (Position Closed) | View |
| 2023-02-08 5:21 pm Unchanged | 13G | Sagaliam Acquisition Corp. SAGA | K2 PRINCIPAL FUND L.P. | 0 0% | 0 (Unchanged) | View |
| 2023-02-08 5:06 pm Unchanged | 13G | Relativity Acquisition Corp. RACY | K2 PRINCIPAL FUND L.P. | 0 0% | 0 (Unchanged) | View |
| 2023-02-07 7:00 pm Sale | 13G | AVROBIO, Inc. AVRO | K2 PRINCIPAL FUND L.P. | 0 0% | -2,235,868 (Position Closed) | View |
| 2022-08-31 6:13 pm Purchase | 13G | TCR2 Therapeutics Inc. TCRR | K2 PRINCIPAL FUND L.P. | 1,950,628 5.05% | 1,950,628 (New Position) | View |
| 2022-08-31 5:49 pm Purchase | 13G | Solid Biosciences Inc. SLDB | K2 PRINCIPAL FUND L.P. | 5,709,200 5.05% | 5,709,200 (New Position) | View |
| 2022-07-29 6:57 pm Purchase | 13G | AVROBIO, Inc. AVRO | K2 PRINCIPAL FUND L.P. | 2,235,868 5.12% | 2,235,868 (New Position) | View |
| 2022-07-15 6:03 pm Purchase | 13G | ARS Pharmaceuticals, Inc. SPRY | K2 PRINCIPAL FUND L.P. | 1,906,618 5.41% | 1,906,618 (New Position) | View |
| 2022-03-22 5:08 pm Purchase | 13G | Goldenstone Acquisition Limited GDST | K2 PRINCIPAL FUND L.P. | 375,000 5.66% | 375,000 (New Position) | View |
| 2022-02-16 5:00 pm Purchase | 13G | Relativity Acquisition Corp. RACY | K2 PRINCIPAL FUND L.P. | 670,000 5.36% | 670,000 (New Position) | View |
| 2022-01-31 6:21 pm Sale | 13G | Pasithea Therapeutics Corp. KTTA | K2 PRINCIPAL FUND L.P. | 1,094,418 4.99% | -605,582 (-35.62%) | View |
| 2022-01-27 6:54 pm Sale | 13G | Welsbach Technology Metals Acquisition Corp. WTMA | K2 PRINCIPAL FUND L.P. | 436,100 4.49% | -63,900 (-12.78%) | View |
| 2022-01-26 5:25 pm Sale | 13G | Ignyte Acquisition Corp. IGNY | K2 PRINCIPAL FUND L.P. | 259,958 3.57% | -152,693 (-37.00%) | View |